Pretreatment Prognostic Nutritional Index Predicts Progression-Free Survival in BCLC Stage C Hepatocellular Carcinoma Treated with Sorafenib.

Authors

Umut Aydın, Mustafa Dikilitaş, İpek Balıkçı Çiçek, Ömer Arif Pamuk, Zehra Sadak Öcal, Yurdagül Danacı, Elanaz Alizade

Published in

Cancer management and research. Volume 18. Pages 621105. Epub Jul 14, 2026.

Abstract

Systemic inflammation and nutritional status are key determinants of tumor progression in advanced hepatocellular carcinoma (HCC). This study aimed to evaluate the prognostic significance of inflammation and nutrition based indices in patients with BCLC stage C HCC treated with sorafenib.
This retrospective cohort study included 109 patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC who received sorafenib as first line systemic therapy. A complete-case approach was used for multivariate Cox regression analysis. Progression-free survival (PFS) was defined according to RECIST version 1.1. Kaplan-Meier survival analysis and Cox proportional hazards regression models were used to assess prognostic factors.
In Kaplan-Meier and univariate Cox analyses, several inflammation- and nutrition-based indices, including NLR, PLR, SII, mGPS, PI, and ALBI grade, were significantly associated with PFS. Although the total cohort included 109 patients, the final multivariate Cox regression model for PNI included 78 complete-case patients. In this model, low prognostic nutritional index (PNI) (HR: 2.36, 95% CI: 1.14-4.87, p=0.020) and prior local ablative treatment (HR: 0.45, 95% CI: 0.24-0.83, p=0.011) remained independently associated with PFS.
Pretreatment low PNI was independently associated with shorter progression-free survival in patients with BCLC stage C HCC treated with sorafenib. Other inflammation and nutrition-based indices were associated with PFS in univariate analyses but did not retain independent prognostic significance after adjustment. PNI may serve as a simple prognostic marker for risk stratification in real-world settings, although external validation is required.

PMID:
42471988
Bibliographic data and abstract were imported from PubMed on 19 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.